Recent developments of interest in cardiovascular medicine
In response to the FDA's updated safety notification for paclitaxel-coated or eluting peripheral artery devices, Philips and Medtronic said they remain confident in their devices. Philips said it will continue enrollment and follow-up of clinical trials with its Stellarex drug-coated balloon; Medtronic emphasized that none of the data has yet been able to demonstrate causality of the excess mortality risk.